NEW YORK (GenomeWeb News) - The Ontario Genomics Institute has made a second investment of Can$50,000 (US$44,687) in Amorfix Life Sciences to support development of a blood test for Alzheimer's disease, Amorfix said today.
Amofrix issued 47,619 common shares and 23,810 warrants to Genomics Ontario, the investment arm of the institute.
Each warrant entitles the holder to purchase one common share of Amorfix at an exercise price of $1.05 for a term of two years. Both the shares and warrants are subject to a four-month hold period.
Amorfix is developing a blood test for Alzheimer’s disease, EP-AD, based upon its patent-pending Epitope Protection technology.
OGI made its first investment in January.